<table>
<thead>
<tr>
<th>Title</th>
<th>A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Kanai, Masashi; Yoshimura, Kenichi; Asada, Masanori; Imaizumi, Atsushi; Suzuki, Chihiro; Matsumoto, Shigemi; Nishimura, Takafumi; Mori, Yukiko; Masui, Toshihiko; Kawaguchi, Yoshiya; Yanagihara, Kazuhiro; Yazumi, Shujiro; Chiba, Tsutomu; Guha, Sushovan; Aggarwal, Bharat B</td>
</tr>
<tr>
<td>Citation</td>
<td>Cancer chemotherapy and pharmacology (2011), 68(1): 157-164</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2011-07</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/143578">http://hdl.handle.net/2433/143578</a></td>
</tr>
<tr>
<td>Right</td>
<td>The final publication is available at <a href="http://www.springerlink.com">www.springerlink.com</a>; ここの論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>author</td>
</tr>
</tbody>
</table>
A Phase I/II Study of Complementary Therapy Using Curcumin for Patients with Gemcitabine-Resistant Pancreatic Cancer

Masashi Kanai1*, Kenichi Yoshimura2, Masanori Asada3, Atsushi Imaizumi4, Chihiro Suzuki2, Shigemi Matsumoto1, Takafumi Nishimura1, Yukiko Mori1, Toshihiko Masui5, Yoshiya Kawaguchi5, Kazuhiro Yanagihara1, Shujiro Yazumi3, Tsutomu Chiba1,6, Sushovan Guha7, Bharat B. Aggarwal8

1) Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan
2) Translational Research Center, Kyoto University Hospital, Kyoto, Japan
3) Kitano Hospital, Osaka, Japan
4) Theravales Corporation, Tokyo, Japan
5) Department of Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan
6) Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto, Japan
7) Department of Gastrointestinal Medicine and Nutrition, MD Anderson Cancer Center, Houston, Texas, USA
8) Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas, USA

*Corresponding author: Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyoku, Kyoto, 606-8507, Japan
Abstract

Purpose: Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of complementary therapy using curcumin with gemcitabine-based chemotherapy.

Methods: Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy. The primary endpoint was safety for phase I and feasibility of oral curcumin for phase II study.

Results: Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79–100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109–223 days) and 1-year survival rate was 19% (4.4–41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested.
Conclusions: Complementary therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation of its efficacy.

Key words: curcumin, gemcitabine, pancreatic cancer
Introduction

Pancreatic cancer is one of the most lethal malignancies worldwide [9, 15]. Although surgery remains the only modality to potentially cure this disease, most patients are diagnosed too late for curative resection. Even after potentially curative resection, this disease relapses in more than 80% of patients and incidence rates are almost coincident with mortality rates [18]. Over the past decade, gemcitabine has been widely used as a standard therapy for advanced pancreatic cancer. Gemcitabine has been proved to improve the median survival time and quality of life in advanced pancreatic cancer patients [4]; however, the prognosis of this disease remains dismal and the development of more effective therapy is urgently needed. Because pancreatic cancer patients often suffer from symptoms related to the cancer itself (e.g. fatigue, appetite loss, pain), it is also very important to maintain a balance between efficacy and quality of life in palliative chemotherapy for pancreatic cancer.

Curcumin is derived from turmeric (Curcuma longa) and is a natural polyphenol. Curcumin has long been used as a food, coloring agents or a traditional medicine. More and more data support the idea that this chemical could be a promising anti-cancer drug for a variety of tumors [6, 10, 19, 23]. Preclinical studies demonstrated curcumin potentiates antitumor activity of gemcitabine against pancreatic cancer [2, 14]. Human studies of curcumin have
shown that this agent can be administered safely at doses of up to 12 g/day [5, 21] and some clinical benefit in patients with pancreatic cancer [7]. Thus, synergic effects of curcumin on gemcitabine in preclinical studies and safety of curcumin monotherapy in clinical studies have been reported; however, at the time of planning this clinical trial in 2008, the safety and feasibility of curcumin in combination with gemcitabine-based chemotherapy had not been reported in a human study. Because the clinical condition of pancreatic cancer patients who failed gemcitabine-based chemotherapy was generally poor, we needed to evaluate whether these patients could tolerate a large amount of daily oral curcumin in combination with gemcitabine-based chemotherapy. Therefore we conducted this phase I/II study to determine the safety and feasibility of oral curcumin in combination with gemcitabine-based chemotherapy in patients with pancreatic cancer.
Patients and methods

Eligibility criteria

Patients with advanced pancreatic cancer who showed disease progression during gemcitabine-based chemotherapy and had no other effective treatment option were eligible if they met the following criteria: histological or radiological confirmation; age ≥20 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; bone marrow function (neutrophil count ≥1500/mm$^3$ and platelet count ≥100,000/mm$^3$), liver function (total bilirubin ≤3 times the upper limit of normal (ULN) and aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤5 times ULN) and renal function (creatinine ≤1.5 mg/dL); adequate oral intake; and provided written informed consent. A criterion of neutrophil count/platelet count was amended to ≥1000/mm$^3$/≥50,000/mm$^3$, respectively, after confirming safety of curcumin in phase I study. Exclusion criteria included: history of severe drug allergy; pregnancy or lactation; and other severe comorbid diseases.

This phase I/II study (UMIN ID 000001386) was conducted in two institutions in Japan. The protocol was approved by the institutional review board at each institution and patient registration and data management were conducted in an independent data center at Translational Research Center, Kyoto University Hospital. All procedures were performed in accordance with the 1964 Declaration of Helsinki.
Curcumin

Curcumin was courteously provided by the Sabinsa Corporation (Piscataway, NJ, USA) in microbead form. One gram of curcuminoids consisted of 900 mg of curcumin, 80 mg of desmethoxycurcumin, and 20 mg of bisdesmethoxycurcumin, which was confirmed by high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) as reported previously [7].

Treatment

As an initial dose level, oral curcumin daily with a dose of 8 g was chosen according to the previous human studies [5, 7, 21]. Oral curcumin was added to the gemcitabine-based chemotherapy (19 patients received gemcitabine/S-1 combination therapy and two patients received gemcitabine monotherapy). Patients were allowed to take 8 g of curcumin separately at their own convenience. The same dose and schedule of gemcitabine-based chemotherapy were applied as used before enrollment onto this study. After the initiation of curcumin intake, the dose and schedule of gemcitabine-based chemotherapy was adjusted at the discretion of individual physicians according to the adverse events observed in the previous cycle. Dose-limiting toxicity (DLT) for the phase I study was defined as follows: Grade 4 leucopenia; Grade 4 neutropenia; Grade 3 or more thrombocytopenia;
non-hematological toxicity of Grade 3 or more (except for the abnormal blood test); patient refusal due to the intolerability of curcumin intake. No dose escalation was planned and dose de-escalation to 6 g/day was pre-planned if more than one DLT among three assessable patients or more than two DLTs among six assessable patients were observed.

Chemotherapy was suspended until recovery if neutrophil count was <1000/mm$^3$, platelet count was <70,000/mm$^3$, total bilirubin was >3.0 mg/dL, AST/ALT was >150 U/L, creatinine was >1.5 mg/dL, stomatitis/diarrhea was Grade 2 or higher, skin rash was Grade 3 or higher, or there was a fever (>38°C) due to infection. During the suspension of gemcitabine-based chemotherapy, curcumin intake was also suspended. The study treatment was continued until intolerability of curcumin intake, unacceptable toxicity related to treatment, patient refusal, or discontinuation of gemcitabine-based chemotherapy because of deterioration of general condition due to disease progression occurred.

**Pretreatment and follow-up evaluation**

Pretreatment evaluation included obtaining the patient's medical history and performing a physical examination, imaging using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), a complete blood cell count, and serum biochemical tests. Physical examinations and blood tests were scheduled on the day of gemcitabine administration. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9)
were measured every month. Toxicity was evaluated using the National Cancer Institute
Common Toxicity Criteria version 3.0 [25].

Sample preparation and measurement of plasma curcumin levels by HPLC-MS/MS

Despite the use of doses of curcumin as high as 8 g/day, previous studies reported very little
free curcumin is found in patient plasma samples [21]. Instead, curcumin is present in
plasma in conjugated (glucuronide and sulfate) forms, which necessitates appropriate
enzymatic hydrolysis of the plasma before detection of free curcumin [7, 26]. In the present
study we measured plasma curcumin levels in five patients who provided written informed
consent for blood draws for this purpose. A 0.1 mL aliquot of each plasma sample was
transferred to a 10 mL glass tube and then 0.11 mL of 0.1 M sodium acetate buffer (pH 5.0)
containing 1000 U β-glucuronidase was added. The resulting solutions were incubated to
hydrolyze the curcumin conjugates at 37°C for 1 h. After 10 μL of Internal Standard (IS)
working solution (500 ng/mL) was added, 0.5 mL of chloroform as extraction solvent was
added. The sample was vortexed for 1 min followed by ultrasonic vibrations for 15 min and
then centrifugation at 1610×g for 5 min. The organic layer was transferred to a 1 mL glass
tube and evaporated to dryness using a centrifuge concentrator. The dried extract was
reconstituted in 100 μL of 50% acetonitrile containing 0.05% formic acid (FA) and then
centrifugated at 7700×g for 10 min. A 10 µL aliquot of supernatant of reconstituted sample solution was injected into the chromatographic system.

The HPLC-MS/MS system consisted of a Prominence micro-LC system (Shimadzu, Kyoto, Japan) and an API 3200 tandem mass spectrometer (Applied Biosystems, Carlsbad, CA, USA) with (+) electrospray ionization (ESI). Samples were put through an Atlantis T3 (2.1×150 mm, 3 µm) (Waters, Milford, USA) C-18 separation column using a gradient of binding solvent (0.05% FA/water) and elution solvent (0.05% FA/acetonitrile) at a flow rate of 0.2 mL/min and a column temperature of 40°C. Separation of samples was conducted by a 35 min linear gradient (5–95% elution solvent). The mass spectrometer was operated under multiple reaction monitoring (MRM) mode with collision energy of 23 eV for curcumin and 33 eV for mepronil. The transitions (precursor to product) monitored were m/z 369→285 for curcumin and 270→119 for mepronil. Chromatograms were integrated using ANALYST software, version 1.5. Stock solutions of curcumin and mepronil were prepared at a concentration of 1000 ng/mL in methanol. The stock solution of mepronil was further diluted with 55% methanol to prepare a calibration standard at a concentration of 100 ng/mL. The stock solution of curcumin was further diluted with 62% methanol to prepare a calibration standard at a concentration of 200 ng/mL. Curcumin solution (200 ng/mL) was diluted with 50% methanol to prepare the following standard solutions: 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25.0,
50.0, and 100.0 ng/mL. These solutions were mixed with IS solution (100 ng/mL) at a ratio of 1:1 to prepare IS-containing calibration samples of 0.2–100.0 ng/mL (curcumin) and 50 ng/mL (mepronil). Stock solution (1000 ng/mL) of mepronil was further diluted with methanol to prepare the IS working solution at a concentration of 500 ng/mL.

Statistical analysis

The primary endpoint was safety for the phase I study and treatment completion rate (TCR) of oral curcumin daily at dose of 8 g for the phase II study. TCR was defined as the percentage of patients after excluding those who were withdrawn from this study because of the intolerability of curcumin. The secondary endpoints for phase II were response rate, overall survival (OS) and compliance rate of curcumin. We considered if less than 50% of patients could tolerate complementary therapy using curcumin, this therapy was not worth for further evaluation. If 80% or more patients could continue this therapy without any clinically relevant toxicity, this therapy was considered to be worth for further evaluation of its efficacy. Therefore, a sample size of 21 patients for phase II was determined to reject the null hypothesis of a TCR of 50% under the expectations of 80% TCR with a significance level of 0.05 and a power of 80%. Among patients with measurable target lesions, the objective response rate was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 [24]. OS was defined as the time from initiation of
complementary therapy using curcumin to death from any cause or the final follow-up, and OS rate was calculated using the Kaplan-Meier method. The final analysis was conducted in April 2010. All analyses were conducted on an intention-to-treat basis and were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results

Patient characteristics

Twenty-one patients were enrolled between September 2008 and August 2009. The patient characteristics are shown in Table 1. The median age was 67 years (range 44–79 years) and 13 patients (62%) were men. Seven of the 21 patients (33%) experienced recurrent disease after undergoing curative surgery and three patients had a history of radiotherapy. All the patients had a history of receiving gemcitabine and S-1. Oral curcumin was added to gemcitabine/S-1 combination therapy in 19 patients (90%) and gemcitabine monotherapy in two patients (10%).

Toxicity

In the phase I study, safety of oral curcumin taken daily at dose of 8 g in combination with gemcitabine-based chemotherapy was evaluated. Since the first three assessable patients completed their first cycle without a DLT at 8 g/day, we selected this amount as the recommended dose for the following phase II study. Overall adverse events are summarized in Table 2. The most common grade 3-4 hematological toxicity was neutropenia (38%) and grade 3-4 non-hematological toxicity was fatigue (10%), both of which were likely to be attributed to the gemcitabine-based chemotherapy or disease progression and considered to be irrelevant to curcumin. Other Grade 3–4 non-hematological adverse events were a
drowsiness \((n=1)\), an anorexia \((n=1)\), an obstruction of gastrointestinal tract \((n=1)\), and an edema \((n=1)\), all of which were also attributed to disease progression.

**Treatment completion rate and compliance rate of curcumin**

No patients were withdrawn from this study because of the intolerability of curcumin, yielding a TCR of 100\% (95\% confidence interval (CI) 84–100\%; \(P<0.001\) under the null hypothesis of a 50\% TCR). At the time of final analysis in April 2010, two patients were still on protocol treatment and the reasons for discontinuation of protocol treatment were disease progression \((n=12)\), adverse events unrelated to curcumin intake \((n=3)\), judgment of physician \((n=1)\), referral to another hospital \((n=1)\), patient’s request \((n=1)\) and protocol violation \((n=1)\). Compliance rate of curcumin is summarized in Table 3. In spite of the high amount required to be taken, 19 patients (90\%) were able to take more than 90\% of the curcumin scheduled in this clinical trial.

**Efficacy**

Seventeen patients (81\%) died during the study period. The median overall survival time was 161 days (95\% CI 109–223 days) and 1-year survival rate was 19\% (95\% CI 4.4–41.4\%)(Figure 1). Among eighteen evaluable patients, no patients experienced a partial or complete response and five patients (28\%) demonstrated stable disease according to RECIST. Median time to treatment failure was 71 days (95\% CI 58–126 days)(Figure 2).
Curcumin pharmacology

Plasma curcumin levels were measured in five patients. We measured curcumin levels following digestion of plasma with combined glucuronidase and sulfatase enzymes. The data on plasma curcumin levels and information about duration of curcumin intake and time of blood draw after final curcumin intake are summarized in Table 4. Except for one patient who demonstrated a plasma curcumin level of 412 ng/ml, curcumin levels ranged from 29 to 91 ng/ml, which was comparable with the previous study [7, 21].
Discussion

Curcumin has been reported to modulate a variety of molecules which play an important role in cancer progression. One of the major targets of curcumin is NF-κB, which regulates the expression of a number of genes involved in antiapoptosis (Bcl-2, Bcl-xL), proliferation (cyclin D1, c-myc), angiogenesis (vascular endothelial growth factor (VEGF), interleukin-8), and invasion (matrix metalloproteinases) [1, 11, 13, 16]. Several preclinical studies have also reported the synergic effect of curcumin in combination with cytotoxic agents. Synergic inhibitory effects of curcumin and 5-fluorouracil on the growth of cancer cell lines have been demonstrated [8, 12]. Vinorelbine-mediated apoptosis is also enhanced by curcumin in squamous lung cancer cell line [20]. Kunnumakkara et al. demonstrated that curcumin potentiates the antitumor effects of gemcitabine in pancreatic cancer and suppresses NF-κB-regulated genes in vitro and in vivo [14]; however, we have no data about the safety and feasibility of curcumin in combination with gemcitabine-based chemotherapy in human studies and we conducted current study to evaluate whether pancreatic patients could tolerate large amount of daily oral curcumin in combination with gemcitabine-based chemotherapy. The toxicity profile of this study was comparable with that observed in pancreatic cancer patients treated with gemcitabine/S-1 combination therapy [29]. Therefore, we considered adding oral curcumin to gemcitabine-based chemotherapy did not increase
the risk of clinically relevant toxicity. No patients were withdrawn from this study because of the intolerability of curcumin and a high compliance rate was achieved in spite of the poor clinical condition after failure of gemcitabine-based chemotherapy. In fact, the median compliance rate of oral curcumin was 100% (range 79–100%), as shown in Table 3, which strongly supported the minimal toxicity of this agent in cancer patients who were receiving concomitant chemotherapy. Furthermore, cumulative toxicity of curcumin was not observed in this study and four patients could continue curcumin intake for more than 6 months without any significant toxicity, which supports the safety of this agent for long-term use. Since pancreatic cancer patients suffer from symptoms related to cancer itself, the low toxicity of this agent is a great advantage for its clinical application in cancer treatment. Some previous clinical studies indicated the risk of diarrhea with curcumin intake [10, 21]. In our study, among four cases of grade 1 diarrhea, two cases could have been attributed to curcumin, but this did not interrupt curcumin intake or gemcitabine-based chemotherapy. We speculated that allowing patients to take curcumin separately reduced the risk of osmotic diarrhea caused by large amounts of curcumin taken at once. Another possible explanation was that patients with pancreatic cancer often suffered from constipation due to peritonitis carcinomatosa or side effect of taking morphine and these backgrounds might have attenuated the risk of diarrhea. In consistent with our current study, Bayet-Robert et al.
recently conducted phase I study of docetaxel plus curcumin in breast cancer patients and reported the safety of oral curcumin at a dose of 6 g/day for 7 consecutive days every 3 weeks [3].

As Oettle et al. reported that median survival time after failure of first-line gemcitabine therapy was only 10 weeks in patients receiving best supportive care alone [17], the prognosis of pancreatic cancer patients who failed gemcitabine-based chemotherapy was very poor. Therefore, a median survival time of 161 days (95% CI 109–223 days) and a 1-year survival rate of 19% (95% CI 4.4–41.4%) in our current study were encouraging and warranted further investigation. Interestingly, several patients reported an improvement of cancer- or chemotherapy-related symptoms (e.g. fatigue, pain, constipation) after the initiation of curcumin intake. Unfortunately the quality-of-life score was not included in the pre-specified endpoints in our current study and these changes might be solely attributed to placebo effects; however, data from several basic studies support our current observation. Curcumin has been shown to improve depressive-like behaviors in mice with an increase in serotonin, noradrenaline, and dopamine levels in the brain [27, 28] or attenuate hyperalgesia in a mouse model of neuropathic pain [22]. It is very important to maintain quality of life in palliative chemotherapy for pancreatic cancer and the improvement of cancer- or chemotherapy-related symptoms could increase the compliance to chemotherapy,
which largely affects the efficacy of chemotherapy and overall survival. More clinical trials are needed to determine the efficacy of curcumin from viewpoint of quality of life in cancer patients.

Plasma curcumin levels were measured in five patients. Except for one patient, our current results were almost consistent with a previous study reporting that steady-state curcumin level ranged from 22 to 41 ng/ml [7]. Furthermore, current results demonstrated a cumulative increase in curcumin levels was unlikely after long-term intake. Poor bioavailability is the major weak point of curcumin when considering its clinical application. Since basic studies suggested that a microgram range of curcumin in target tissue is necessary to achieve anti-cancer effects, many researchers are focusing on improving the bioavailability of curcumin to get more benefits from this promising agent. Recently, pulverized curcumin was developed in Japan (Theravalue Corporation, Tokyo, Japan) to improve the agent’s bioavailability. If we could achieve higher plasma curcumin levels, we could expect more benefits from curcumin in the treatment of cancer patients and we are now planning clinical trials to evaluate the efficacy of this newly developed curcumin.

In conclusion, our data demonstrated that administration of oral curcumin in combination with gemcitabine-based chemotherapy is safe and well-tolerated in pancreatic cancer
patients. More studies are now underway to establish the efficacy of this promising agent in cancer treatment.

Acknowledgement

We thank Hiroe Tada and Miyuki Niimi for their contributions to data management, Emi Shimada and Dr Vladimir Badmaev for their contributions to curcumin shipment.

Grant support

This work was supported by the Grant-in-Aid for Young Scientists (21790661) from the Japan Society for the Promotion of Science, Japanese Research Foundation for Clinical Pharmacology and Smoking Research Foundation.
### Table 1. Patient characteristics (n=21)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Description</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>13 (62.0%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>8 (38.0%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>Median</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>44–79</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Histological confirmation</td>
<td>19 (90.0%)</td>
</tr>
<tr>
<td></td>
<td>Imaging test</td>
<td>2 (10.0%)</td>
</tr>
<tr>
<td>History of anti-cancer drugs</td>
<td>Gemcitabine</td>
<td>21 (100.0%)</td>
</tr>
<tr>
<td></td>
<td>S-1</td>
<td>21 (100.0%)</td>
</tr>
<tr>
<td>History of surgery</td>
<td></td>
<td>7 (33%)</td>
</tr>
<tr>
<td>History of radiotherapy</td>
<td></td>
<td>3 (14%)</td>
</tr>
<tr>
<td>Concomitant chemotherapy</td>
<td>Gemcitabine/S-1</td>
<td>19 (90%)</td>
</tr>
<tr>
<td></td>
<td>Gemcitabine</td>
<td>2 (10%)</td>
</tr>
</tbody>
</table>
Table 2. Toxicity

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>10%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>5%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Hand-foot rash</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>0%</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Nausea</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>1</td>
<td>5</td>
<td>7</td>
<td>0</td>
<td>33%</td>
</tr>
<tr>
<td>Neutrophil</td>
<td>0</td>
<td>4</td>
<td>8</td>
<td>0</td>
<td>38%</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>3</td>
<td>9</td>
<td>4</td>
<td>0</td>
<td>19%</td>
</tr>
<tr>
<td>Platelets</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>10%</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>10%</td>
</tr>
<tr>
<td>AST</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>ALT</td>
<td>7</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Creatinine</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Albumin</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>ALP</td>
<td>11</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Others (≧≧ Grade 3)</td>
<td>–</td>
<td>–</td>
<td>4</td>
<td>0</td>
<td>19%</td>
</tr>
</tbody>
</table>
Table 3. Compliance rate

<table>
<thead>
<tr>
<th>Compliance Rate ( (n=21) )</th>
<th>( n )</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.70</td>
<td>0</td>
</tr>
<tr>
<td>( \geq 0.70, &lt;0.80 )</td>
<td>1</td>
</tr>
<tr>
<td>( \geq 0.80, &lt;0.90 )</td>
<td>1</td>
</tr>
<tr>
<td>( \geq 0.90, &lt;0.95 )</td>
<td>1</td>
</tr>
<tr>
<td>( \geq 0.95, &lt;1.00 )</td>
<td>4</td>
</tr>
<tr>
<td>1.00</td>
<td>14</td>
</tr>
</tbody>
</table>

Compliance rate \( \geq 0.90 \) \( 90\% \)  
(95% CI) \( 70–99\% \)
Table 4. Plasma curcumin levels and patient information

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)</th>
<th>Gender</th>
<th>Duration of curcumin intake</th>
<th>Plasma curcumin levels (ng/ml)</th>
<th>Time of blood draw after final curcumin intake (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>69</td>
<td>Female</td>
<td>14 months</td>
<td>29</td>
<td>24</td>
</tr>
<tr>
<td>Case 2</td>
<td>75</td>
<td>Male</td>
<td>4 months</td>
<td>55</td>
<td>4</td>
</tr>
<tr>
<td>Case 3</td>
<td>67</td>
<td>Female</td>
<td>6 months</td>
<td>85</td>
<td>1</td>
</tr>
<tr>
<td>Case 4</td>
<td>75</td>
<td>Female</td>
<td>6 months</td>
<td>91</td>
<td>9</td>
</tr>
<tr>
<td>Case 5</td>
<td>70</td>
<td>Male</td>
<td>3 months</td>
<td>412</td>
<td>4</td>
</tr>
</tbody>
</table>
Figure 1. Overall survival (n=21)
MST, median survival time.
Figure 2. Time to treatment failure ($n=21$)

TTF, time to treatment failure

TTF 71 days
(95% CI; 58-126 days)
References

Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and
antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase
and Akt activation. Mol Pharmacol 69: 195-206

PA, Sarkar FH (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Cancer Res 70: 3606-17

trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Cancer Biol Ther 9: 8-14

Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line
therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:
2403-13


Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21: 8852-61


